We focused on the best known pathways in CML involving the activation of BCR-ABL1 kinase and downstream signaling such as JAK/STAT5, PI3K/AKT, and mTOR/NF-κB [38]. This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.